| Literature DB >> 29218565 |
M J Welmers-van de Poll1,2, J J Roest3, T van der Stouwe4, A L van den Akker4, G J J M Stams4, V Escudero5, G J Overbeek4, J J W de Swart6.
Abstract
Alliance has been shown to predict treatment outcome in family-involved treatment for youth problems in several studies. However, meta-analytic research on alliance in family-involved treatment is scarce, and to date, no meta-analytic study on the alliance-outcome association in this field has paid attention to moderating variables. We included 28 studies reporting on the alliance-outcome association in 21 independent study samples of families receiving family-involved treatment for youth problems (N = 2126 families, M age youth ranging from 10.6 to 16.1). We performed three multilevel meta-analyses of the associations between three types of alliance processes and treatment outcome, and of several moderator variables. The quality of the alliance was significantly associated with treatment outcome (r = .183, p < .001). Correlations were significantly stronger when alliance scores of different measurement moments were averaged or added, when families were help-seeking rather than receiving mandated care and when studies included younger children. The correlation between alliance improvement and treatment outcome just failed to reached significance (r = .281, p = .067), and no significant correlation was found between split alliances and treatment outcome (r = .106, p = .343). However, the number of included studies reporting on alliance change scores or split alliances was small. Our findings demonstrate that alliance plays a small but significant role in the effectiveness of family-involved treatment. Future research should focus on investigating the more complex systemic aspects of alliance to gain fuller understanding of the dynamic role of alliance in working with families.Entities:
Keywords: Family-based treatment; Multilevel meta-analysis; Therapeutic alliance; Treatment outcomes; Working alliance
Mesh:
Year: 2018 PMID: 29218565 PMCID: PMC5899120 DOI: 10.1007/s10567-017-0249-y
Source DB: PubMed Journal: Clin Child Fam Psychol Rev ISSN: 1096-4037
Fig. 1Flow diagram for the search and identification of studies
Summary of studies included in the meta-analysis
| Study | Study qualityb | Treatment model | Treatment setting | Type of TA | TA measure | TA timing | TA Rater | Outcome domain | Outcome timing | Outcome rater |
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bachler et al. ( | 30 | TAF | HB | P/Yc | CP-TAF | Imp | T | GT, PF, YS | EOT | P | 304 | n.r. | 8 |
| Bennun ( | 6 | FT | C | P | TS | E | P | GT, YS + PF | EOT | P | 35 | 26 | 5 |
| Y | TS | E | Y | YS + PF | EOT | P | 17 | 17 | |||||
| Chinchilla ( | 27 | MDFT | n.r. | Y | VTAS-R | E | O | R, YS | EOT, FU | Y, P, OM | 68 | 66 | 11 |
| Dauber ( | 25 | MDFT | n.r. | Y | VTAS-R | E | O | YS | EOT, FU | Y | 63 | 61 | 6 |
| Escudero et al. ( | 24 | FT | C | Y + P | SOFTA-O | E, M | O | GT | DT | Y, P | 37 | 82 | 16 |
| F | SOFTA-O | E, M | O | GT | DT | Y, P | 82 | ||||||
| Feder and Diamond | 20 | ABFT | C | P | VTAS-R | M | O | YS | EOT | Y | 19 | 19 | 2 |
| Flicker et al. ( | 22 | FFT | C | Y | VTAS-R | E | O | R | EOT | T | 86 | 43 | 6 |
| P | VTAS-R | E | O | R | EOT | T | 43 | ||||||
| S | VTAS-R | E | O | R | EOT | T | 43 | ||||||
| Forsberg et al. ( | 18 | FBT | C | P | WAI-O | E | O | YS | EOT | OM | 38 | 61 | 3 |
| S | WAI-O | E | O | YS | EOT | OM | 99 | ||||||
| Forsberg ( | 15 | FBT | C | Y + P | WAI-O | E | O | YS | EOT | Y | 38 | 99 | 1 |
| Friedlander et al. ( | 19 | FT | C | F | SOFTA-O | E | O | GT | DT | P | 27 | n.r. | 2 |
| Friedlander et al. ( | 17 | FT | C | Y | SOFTA-S | E, M | Y | GT | DT | Y, P | 20 | 20 | 4 |
| P | SOFTA-S | E, M | P | GT | DT | Y, P | 36 | ||||||
| Glueckauf et al. ( | 22 | IFCM | n.r. | Y | WAI-S | E + M (A) | Y | YS, GT | EOT | Y | 19 | 19 | 20 |
| P | WAI-S | E + M (A) | P | YS, GT | EOT | P | 19 | ||||||
| Hawley and Weisz ( | 29 | CB MH | C | Y | TASC | L | Y | R, YS | EOT | OM, T, Y, P | 65 | 65 | 10 |
| P | TASC | L | P | R, YS | EOT | OM, T, Y, P | 65 | ||||||
| Hogue et al. ( | 28 | MDFT | n.r. | Y | VTAS-R | E | O | YS | EOT, FU | Y, P | 44 | 44 | 20 |
| P | VTAS-R | E | O | YS | EOT, FU | Y, P | n.r. | ||||||
| Isserlin and Couturier ( | 18 | FBT | C | Y | SOFTA-O | E, M, L | O | YS, R | EOT | OM, Y, P | 14 | 14 | 75 |
| P | SOFTA-O | E, M, L | O | YS, R | EOT | OM, Y, P | n.r. | ||||||
| F | SOFTA-O | E, M, L | O | YS, R | EOT | OM, Y, P | n.r. | ||||||
| Johnson et al. ( | 27 | HB FT | HB | Y + P | FTAS | L | Y, P | YS | EOT | Y + P | 225 | 456 | 6 |
| Johnson et al. ( | 27 | HB FT | HB | Y | FTAS | L | Y | YS, PF | EOT | Y | 43 | 16 | 18 |
| P | FTAS | L | P | YS, PF | EOT | P | 45 | ||||||
| Keeley et al. ( | 27 | FB CBT | C | Y | TASC | E, M | C, T | YS | EOT | Y, P | 23 | 22 | 16 |
| P | WAI | E, M | P, T | YS | EOT | Y, P | 22 | ||||||
| Kim ( | 11 | SFBT | C | Y | RRS | E | Y | YS | EOT | Y | 25 | 21 | 20 |
| P | RRS | E | P | PF | EOT | P | 22 | ||||||
| Y + P | RRS | E | Y, P | PF | EOT | Y, P | n.r. | ||||||
| S | RRS | E | Y, P | PF | EOT | Y, P | n.r. | ||||||
| Lange (in prep.) | 29 | MST | HB | P | TAM-R | Imp, E, M, L | P | YS | EOT, FU | P | 848 | 774 | 18 |
| Pereira et al. ( | 17 | FBT | C | Y | WAI-O | E, L | O | R, YS | EOT, DT | OM | 41 | 36 | 18 |
| P | WAI-O | E, L | O | R, YS | EOT, DT | OM | 31 | ||||||
| Rienecke et al. ( | 23 | FBT PHP | C, H | Y | WAI-S | E, L | Y | R, YS | EOT | O | 56 | 56 | 17 |
| P | WAI-S | E, L | P | R, YS | EOT | O | 40 | ||||||
| Robbins et al. ( | 20 | MDFT | n.r. | Y + P | VTAS-R | E | O | R | EOT | OM | 30 | n.r. | 1 |
| Robbins et al. ( | 23 | BSFT | n.r. | Y | VTAS-R | E | O | R | EOT | OM | 31 | 23 | 14 |
| P | VTAS-R | E | O | R | EOT | OM | 23 | ||||||
| Y + P | VTAS-R | E | O | R | EOT | OM | n.r. | ||||||
| S | VTAS-R | E | O | R | EOT | OM | n.r. | ||||||
| Robbins et al. ( | 16 | FFT | n.r. | Y | VTAS-R | E | O | R | EOT | OM | 34 | 29 | 13 |
| P | VTAS-R | E | O | R | EOT | OM | 29 | ||||||
| Y + P | VTAS-R | E | O | R | EOT | OM | n.r. | ||||||
| S | VTAS-R | E | O | R | EOT | OM | n.r. | ||||||
| Shelef and Diamond ( | 26 | MDFT | n.r. | Y | VTAS-R(SF) | E, M, L | O | R, YS | EOT | OM | 86 | 45 | 4 |
| P | VTAS-R(SF) | E, M, L | O | R | EOT | OM | 34 | ||||||
| Y + P | VTAS-R(SF) | E, M, L | O | R | EOT | OM, Y | 68 | ||||||
| Shelef et al. ( | 27 | MDFT | n.r. | Y | WAI, VTAS-R | E | Y, O | YS, R | EOT, FT | Y, OM | 91 | 59 | 23 |
| P | VTAS-R | E | O | R | EOT | OM | 65 | ||||||
| Y + P | VTAS-R | E | O | R | EOT, FU | OM | 110 | ||||||
| Zaitsoff et al. ( | 20 | FBT | C | Y | HRQ | ML | Y | YS | EOT | Y | 40 | 40 | 4 |
TAF therapeutische ambulante familienbetreung; FT family therapy, no specific model; MDFT multidimensional family therapy; ABFT attachment-based family therapy; FFT functional family therapy; FBT family-based treatment; IFCM issue-specific single-family counseling; CB MH community-based mental health; HB FT home-based family therapy; FB CBT family-based cognitive behavioral therapy; SFBT solution-focused brief therapy; FBT PHP family-based therapy partial hospitalization program; BSFT brief strategic family therapy; C clinic; HB home-based; H hospital; TA therapeutic alliance; Y youth; P parent; Y + P averaged or added scores of youth and parent; F within family; S Split: difference scores (youth and parent scores subtracted); T therapist; O observer; CP-TAF compliance collaboration scale for Therapeutische Ambulante Familienbetreung; TS therapist scale; VTAS(-R) Vanderbilt therapeutic alliance scale (–Revised); SOFTA (-O/S) system for observing family therapy alliances (-observer/self-report); WAI(-S/O) working alliance inventory (short form/observer version); TASC therapeutic alliance scale for children; FTAS family therapy alliance scale; HAQ helping alliance questionnaire; TAS therapeutic alliance scale; RRS relationship rating scale; HRQ helping relationship questionnaire; E early treatment; M midtreatment; L late treatment; A multiple moments averaged or added; Imp improvement (alliance change scores); YS youth symptom severity or functioning; PF parental or family functioning; R retention; GT goal attainment or therapeutic progress; EOT end of treatment; FU follow-up; DT during treatment; OM objectified measure; n. r. not reported
aIndicates doctoral dissertation
bStudy quality reflects the study quality checklist score
cAlliance was measured for the primary participant of the therapy, which could be either parent or adolescent
dSample sizes are based on a mean of all available reported analyses
eNumber of computed effect sizes per study
fStudy was included in previous meta-analysis on alliance in family therapy (Friedlander et al. 2011)
1,2,3,4,5Studies reported on the same or overlapping samples
Sample characteristics of studies included in the meta-analysis
| Study |
| Problem type | Referral to treatment |
| % male youth | % male adult | % non-caucasian | % non-caucasian therapists |
|---|---|---|---|---|---|---|---|---|
| Bachler et al. ( | 304 | Multiproblem families | M | 14.6 | 49 | 35 | n.r. | n.r. |
| Bennun ( | 35 | Mixed | HS | n.r. | n.r. | n.r. | n.r. | n.r. |
| Chinchilla ( | 68 | Substance abuse | Mx | 15.3 | 80 | n.r. | 83 | 50 |
| Dauber ( | 63 | Substance abuse | Mx | 15.3 | 79 | n.r. | 81 | 60 |
| Escudero et al. ( | 37 | Mixed | HS | 15.0 | 40 | 36 | 0 | 0 |
| Feder and Diamond | 19 | Internalizing problems | HS | 15.5 | 5 | 16 | 74 | 0 |
| Flicker et al. ( | 86 | Substance abuse | Mx | 15.7 | 84 | n.r. | 50 | 33 |
| Forsberg et al. ( | 38 | Eating disorders | HS | 14.0 | 13 | 41 | 24 | n.r. |
| Forsberg ( | 39 | Eating disorders | HS | 14.0 | 13 | 41 | 24 | n.r. |
| Friedlander et al. ( | 27 | Mixed | R | 10.2 | n.r. | 33 | 7 | 10 |
| Friedlander et al. ( | 20 | Mixed | R | 13.2 | 33 | 41 | 10 | 11 |
| Glueckauf et al. ( | 19 | Epilepsy with behavioral problems | R | 13.9 | 53 | 41 | 11 | n.r. |
| Hawley and Weisz ( | 65 | Mixed | HS | 11.9 | 59 | 11 | 63 | n.r. |
| Hogue et al. ( | 44 | Substance abuse | Mx | 15.47 | 81 | n.r. | 80 | 60 |
| Isserlin and Couturier ( | 14 | Eating disorders | HS | 14.0 | 0 | n.r. | n.r. | n.r. |
| Johnson et al. ( | 225 | Multiproblem families | M | 14.4 | n.r. | 36 | 15 | n.r. |
| Johnson et al. ( | 43 | Multiproblem families | M | 14.0 | n.r. | 27 | 19 | n.r. |
| Kim ( | 25 | Mixed | HS | 13.1 | 48 | 19 | 4 | n.r. |
| Lange (in prep.) | 848 | Externalizing problems | M | 15.3 | 66 | 17 | n.r. | n.r. |
| Pereira et al. ( | 41 | Eating disorders | R | 15.1 | 9 | n.r. | 26 | n.r. |
| Rienecke et al. ( | 56 | Eating disorders | HS | 15.8 | 7 | 37 | 7 | 0 |
| Robbins et al. ( | 30 | Substance abuse | Mx | 14.9 | 80 | n.r. | 83 | 20 |
| Robbins et al. ( | 31 | Substance abuse | n.r. | 15.7 | 71 | 43 | 100 | n.r. |
| Robbins et al. ( | 34 | Substance abuse | Mx | 15.0 | 59 | n.r. | n.r. | n.r. |
| Shelef and Diamond ( | 86 | Substance abuse | Mx | 16.0 | 73 | n.r. | 51 | 33 |
| Shelef et al. ( | 91 | Substance abuse | Mx | 16.0 | 85 | n.r. | 53 | 33 |
| Zaitsoff et al. ( | 40 | Eating disorders | n.r. | 16.1 | 3 | n.r. | 36 | n.r. |
HS help-seeking; R recruited (for study); M mandated; Mx mixed; n.r. not reported
1,2,3,4,5Studies reported on the same or overlapping samples
Results for the overall mean effect sizes based on three-level mixed effects models
| Type of effect size | # studies | # ES | Mean | 95% CI | Sig. mean | % var. level 1 | σ2 level 2 | % var. level 2 | σ2 level 3 | % Var. level 3 |
|---|---|---|---|---|---|---|---|---|---|---|
| Level of alliance–outcome1 | 20 | 329 | .183 (.044) | .100, .265 | < .001*** | 19.6 | .044*** | 48.2 | .029*** | 32.2 |
| Split alliance–outcome2 | 5 | 17 | .106 (.109) | − .124, .327 | .343 | 42.2 | .015 | 15.3 | .042* | 42.5 |
| Alliance change score–outcome3 | 3 | 15 | .281 (.145) | − .023, .538 | .067 | 5.2 | .004 | 6.4 | .058*** | 88.3 |
ES effect size; CI confidence interval; σ2 level 2 variance between effect sizes (within studies); σ2 level 3 variance between effect sizes (between studies)
The number of studies reflects the number of independent samples
*p < .05, **p < .01, ***p < .001
Results of Egger analysis: 1 t = 12.58, p < .001; 2 t = − .48, p = .64; 3 t = 6.85, p < .001
Results of moderator analyses based on three-level mixed effects models for level of alliance and treatment outcome
| Moderator | # studies | # ES | Mean | 95% CI | β (95% CI) | Test statistic |
| σ2 level 2 | σ2 level 3 |
|---|---|---|---|---|---|---|---|---|---|
| Study quality | 20 | 329 | .421 (.160)** | .130, .645 | − .012 (− .027, .002) |
| .091 | .043*** | .031*** |
| Sample characteristics | |||||||||
| Problem type general | 20 | 329 |
| .155 | .044*** | .028*** | |||
| Youth problems | 16 | 278 | .154 (.048)** | .060, .244 | |||||
| Mixed youth parent/family problems | 4 | 51 | .299 (.096)** | .117,.461 | .152 (− .058, .350) | ||||
| Problem type | 20 | 329 |
| .339 | .044*** | .027*** | |||
| Drug abuse youth | 3 | 77 | .112 (.093) | − .070, .287 | |||||
| Eating disorders youth | 4 | 116 | .206 (.086)* | .040, .361 | .097 (− .151, .332) | ||||
| Internalizing problems youth | 1 | 14 | .444 (.156)** | .167, .656 | .350 (− .007, .619)* | ||||
| Externalizing problems youth | 1 | 15 | − .004 (.172) | − .347, .326 | − .116 (− .466, .265) | ||||
| Multiproblem families | 2 | 34 | .118 (.125) | − .128, .352 | .007 (− .293, .319) | ||||
| Mixed | 5 | 73 | .203 (.077)** | .054, .344 | .093 (− .143, .319) | ||||
| Average age youth | 18 | 313 | .794 (.286)*** | .465, .930 | − .062 (− .101, − .022)** |
| .002** | .045*** | .011*** |
| % Male youth | 18 | 298 | .424 (.084)** | .082 (.390) | − .158 (− .431, .140) |
| .296 | .045*** | .029*** |
| % Male adult | 11 | 105 | .140 (.049)** | .044, .234 | .059 (− .094, .211) |
| .446 | .000 | .016*** |
| % Non-caucasian | 17 | 238 | .199 (.059)*** | .085, .309 | − .071 (− .320, .178) |
| .575 | .047*** | .020*** |
| % Non-caucasian therapists | 7 | 110 | .193 (.081)* | .035, .341 | − .186 (− .671, .299) |
| .448 | .078*** | .013 |
| Referral source | 18 | 317 |
| .033* | .044*** | .023*** | |||
| Recruited for study | 3 | 44 | .264 (.100)** | .073, .436 | |||||
| Help-seeking | 9 | 154 | .277 (.061)*** | .161, .383 | .014 (− .214, .239) | ||||
| Mandated | 1 | 24 | .116 (.160) | − .198, .411 | − .151 (− .527, .219) | ||||
| Mixed mandated/help-seeking | 5 | 95 | .011 (.075) | − .136, .159 | − .253 (− .466, − .012)* | ||||
| Treatment characteristics | |||||||||
| Treatment model | 20 | 329 |
| .071 | .044** | .019** | |||
| MDFT | 2 | 65 | .114 (.102) | − .088, .308 | |||||
| FBT | 5 | 116 | .204 (.075)** | .059, .340 | .091 (− .159, .330) | ||||
| FB CBT | 1 | 12 | .523 (.164)*** | .256, .720 | .435 (.083, 691)* | ||||
| FFT | 2 | 15 | − .124 (.123) | − .353, .119 | − .235 (.506, .078) | ||||
| MST | 1 | 15 | .183 (.074)* | .040, .319 | .070 (− .178, .310) | ||||
| Other | 5 | 58 | .119 (.160) | − .194, .410 | .005 (− .355, .364) | . | |||
| Treatment setting | 15 | 225 |
| .175 | .000 | .037*** | |||
| Home-based | 2 | 39 | .018 (.136) | − .246, .288 | |||||
| Outpatient clinic | 12 | 169 | .265 (.060)*** | .152, .371 | .248 (− .045, .498) | ||||
| Hospital or residential treatment | 1 | 17 | .067 (.194) | − .319, .309 | .049 (− .399, .478) | ||||
| Alliance characteristics | |||||||||
| Type of alliance | 20 | 329 |
| .891 | .045*** | .029*** | |||
| Youth–therapist | 17 | 116 | .195 (.050)*** | .100, .288 | |||||
| Parent–therapist | 18 | 132 | .168 (.048)*** | .075, .259 | − .028, (− .106, .052) | ||||
| (Within) family/therapist | 4 | 33 | .208 (.081)** | .052, .354 | .013 (− .134, .159) | ||||
| Youth + parent–therapist (added or averaged) | 8 | 48 | .191 (.060)** | .075, .301 | − .005 (− .108, .99) | ||||
| Alliance rater | 20 | 329 |
| .628 | .044*** | .029*** | |||
| Youth | 10 | 58 | .179 (.059)** | .065, .289 | |||||
| Parent | 9 | 67 | .184 (.063)** | .063, .300 | .005 (− .105, .115) | ||||
| Therapist | 1 | 6 | .347 (.165)* | .035, .598 | .179 (− .145, .468) | ||||
| Observer | 11 | 193 | .186 (.056)*** | .078, .289 | .007 (− .126, .140) | ||||
| Youth + parent averaged or added | 2 | 5 | .007 (.153) | − .289, .301 | − .172 (− .445, .129) | ||||
| Development of measure | 20 | 329 |
| .248 | .044*** | .028*** | |||
| For individual therapy | 16 | 208 | .272 (.092)** | .099, .429 | |||||
| For family therapy | 4 | 121 | .158 (.049)** | .063, .250 | − .119 (− .313, .084) | ||||
| Alliance construct | 20 | 329 |
| .817 | .045*** | .026*** | |||
| Bond | 5 | 24 | .154 (.080) | − .004, .303 | |||||
| Goal | 3 | 15 | .182 (.096) | − .006, .355 | .028 (− .167, .221) | ||||
| Task | 3 | 15 | .145 (.096) | − .043, .323 | − .009 (− .203, .187) | ||||
| Goal and task | 2 | 54 | .275 (.106)** | .071, .457 | .153 (− .069, .360) | ||||
| Bond, goal and task | 16 | 182 | .164 (.047)*** | .072, .253 | .126 (− .109, .350) | ||||
| Within-family alliance | 3 | 39 | .300 (.099)** | .112, .465 | .011 (− .151, .173) | ||||
| Alliance timing | 20 | 329 |
| .014* | .041*** | .029*** | |||
| Early treatment | 15 | 204 | .153 (.047)** | .062, .242 | |||||
| Midtreatment | 6 | 35 | .205 (.069)** | .072, .330 | .053 (− .070, .174) | ||||
| Late treatment | 7 | 56 | .208 (.067)* | .021, .278 | − .001 (− .124, .122) | ||||
| Averaged or added | 4 | 34 | .326 (.079)*** | .228, .496 | .230 (.090, .360)** | ||||
| Outcome characteristics | |||||||||
| Outcome domain | 20 | 329 |
| .187 | .044*** | .025*** | |||
| Youth symptom severity or functioning | 15 | 222 | .167 (.045)*** | .081, .251 | |||||
| Parental or family functioning | 1 | 6 | .020 (.150) | − .270, .306 | − .148 (− .410, .136) | ||||
| Retention | 9 | 69 | .141 (.055)* | .033, .245 | − .027 (− .121, .067) | ||||
| Goal attainment, therapeutic progress | 4 | 32 | .323 (.089)*** | .158, .470 | .164 (.-017, .335) | ||||
| Outcome rater | 20 | 329 |
| .502 | .044*** | .030*** | |||
| Youth | 11 | 111 | .163 (.054)** | .059, .265 | |||||
| Parent | 9 | 77 | .235 (.057)*** | .125, .337 | .074 (− .026, .171) | ||||
| Therapist | 3 | 14 | .176 (.103) | − .027, .364 | .012 (− .200, .224) | ||||
| Observer | 2 | 10 | .175 (.112) | − .047, .380 | .011 (− .200, .222) | ||||
| Objectified measure | 7 | 89 | .132 (.062)* | .010, .250 | − .032 (− .143, .079) | ||||
| Youth and parent combined | 4 | 27 | .167 (.084)* | .004, .322 | .004 (− .169, .176) | ||||
| Youth and data combined | 1 | 1 | .567 (.298)* | .039, .847 | .445 (− .132, .796) | ||||
| Outcome timing | 20 | 329 | F (2, 326) = .117 | .890 | .044*** | .031*** | |||
| End of treatment | 18 | 257 | .189 (.046)*** | .099, .275 | |||||
| Follow-up | 3 | 42 | .165 (.067)* | .036, .289 | − .024 (− .128, .082) | ||||
| During treatment | 3 | 30 | .168 (.069) | − .019, .344 | − .021 (− .209, .168) | ||||
ES effect size; CI confidence interval; σ2 level 2 variance between effect sizes (within studies); σ2 level 3 variance between effect sizes (between studies)
The number of studies reflects the number of independent samples
*p < .05, **p < .01, ***p < .001
Results of moderator analyses based on three-level mixed effects models for split alliances and treatment outcome
| Moderator | # studies | # ES | Mean | 95% CI | β (95% CI) | Test statistic |
| σ2 level 2 | σ2 level 3 |
|---|---|---|---|---|---|---|---|---|---|
| Study quality | 5 | 17 | .839 (.282)* | .217, .897 | − .041 (− .074, − .008)* |
| .018* | .015 | .007 |
| Sample characteristics | |||||||||
| Problem type | 5 | 17 |
| .019 * | .017 | .002 | |||
| Drug abuse youth | 2 | 8 | − .137 (.093) | − .325, .060 | |||||
| Eating disorders youth | 1 | 2 | .179 (.157) | − .160, .477 | .307 (− .076, .611) | ||||
| Mixed problem types | 2 | 7 | .308 (.105)* | .083, .487 | .419 (.146, .633)** | ||||
| Average age youth | 5 | 17 | .970 (.898) | − .769, 1.000 | − .135 (− .335, .076) |
| .191 | .016 | .030 |
| % Male youth | 5 | 17 | .327 (.274) | − .253, .734 | − .395 (− .887, .517) |
| .383 | .016 | .042 |
| % Male adult | 3 | 13 | .046 (.175) | − .330, .410 | .069 (− .377, .514) |
| .741 | .000 | .069* |
| % Non-caucasian | 4 | 15 | − .106 (.215) | − .518, .346 | .370 (− .076, .816) |
| .097 | .000 | .140 |
| Treatment characteristics | |||||||||
| Treatment model | 5 | 17 |
| .849 | .016 | .078* | |||
| FBT | 1 | 2 | .177 (.307) | − .464, .696 | |||||
| FFT | 2 | 4 | .179 (.220) | − .291, .580 | .002 (− .681, .684) | ||||
| Other | 2 | 11 | .018 (.211) | − .414, .444 | − .159 (− .754, .578) | ||||
| Alliance characteristics | |||||||||
| Alliance rater | 5 | 17 |
| .447 | .016 | .046 | |||
| Observer | 4 | 12 | .062 (.127) | − .207, .323 | |||||
| Youth + parent averaged or added | 1 | 5 | .274 (.244) | − .245, .671 | .216 (− .362, .816) | ||||
| Outcome characteristics | |||||||||
| Outcome domain | 5 | 17 |
| .361 | .016 | .041 | |||
| Youth symptom severity or functioning | 2 | 7 | .229 (.171) | − .134, .538 | |||||
| Retention | 3 | 12 | .024 (.139) | − .267, .311 | .206 (− .593, .258) | ||||
| Outcome rater | 5 | 17 |
| .959 | .017 | .149* | |||
| Youth | 1 | 5 | .274 (.385) | − .535, .821 | |||||
| Therapist | 1 | 2 | .022 (.390) | − .869, .723 | − .260 (− .907, .758) | ||||
| Objectified measure | 2 | 8 | .046 (.281) | − .578, .585 | − .235 (− .865, .687) | ||||
| Youth and objectified measure combined | 1 | 2 | .177 (.423) | − .615, .791 | − .102 (− .876, .818) | ||||
ES effect size; CI confidence interval; σ2 level 2 variance between effect sizes (within studies); σ2 level 3 variance between effect sizes (between studies)
The number of studies reflects the number of independent samples
*p < .05, **p < .01, ***p < .001
Results of moderator analyses based on three-level mixed effects models for alliance change scores and treatment outcome
| Moderator | # studies | # ES | Mean | 95% CI | β (95% CI) | Test statistic |
| σ2 level 2 | σ2 level 3 |
|---|---|---|---|---|---|---|---|---|---|
| Study quality | 3 | 15 | .981 (1.000) | − 1.000, 1.000 | − .070 (− .380, .254) |
| .653 | .004 | .100*** |
| Sample characteristics | |||||||||
| Problem type general | 3 | 15 |
| .777 | .004 | .113** | |||
| Youth problems | 1 | 8 | .248 (.240) | − .270, .654 | |||||
| Mixed youth and parent/family problems | 2 | 7 | .357 (.325) | − .355, .801 | .121 (.653, .771) | ||||
| Problem type | 3 | 15 |
| .007** | .004 | .004 | |||
| Internalizing problems youth | 1 | 4 | .471 (.135)** | .212, .668 | |||||
| Externalizing problems youth | 1 | 3 | .020 (.078) | − .150, .188 | − .455 (− .682, − .149)** | ||||
| Multiproblem families | 1 | 8 | .357 (.072)*** | .214, 485 | − .136 (− .440, .194) | ||||
| Average age youth | 3 | 15 | .878 (.709) | − .497, .997 | − .079 (− .215, .059) |
| .239 | .004 | .045** |
| % Male youth | 3 | 15 | .908 (.762) | − .570, .999 | − .974 (− 1.000, .923) |
| .237 | .004 | .045 |
| % Male adult | 2 | 11 | − .812 (.278)** | − .945, − .449 | 1.000 (− .978, 1.000)*** |
| <.001*** | .004 | .001 |
| % Non-caucasian | 3 | 15 | .374 (.328) | − .305,.801 | − .656 (− 4.455, 3.143) |
| .715 | .004 | .107*** |
| Referral source | 3 | 15 |
| .007** | .004 | .004 | |||
| Help-seeking | 1 | 4 | .471 (.135)** | .212, .668 | |||||
| Mandated | 1 | 8 | .357 (.072)*** | .214, 485 | − .136 (.440, .194) | ||||
| Mixed mandated/help-seeking | 1 | 3 | .020 (.078) | − .150, .188 | − .455 (− .682, − .149)** | ||||
| Treatment characteristics | |||||||||
| Treatment model | 3 | 15 |
| .007** | .004 | .004 | |||
| FB CBT | 1 | 4 | .471 (.135)** | .212, 668 | |||||
| MST | 1 | 3 | .020 (.078) | − .150, .188 | − .491 (− .833, − .149)** | ||||
| Other | 1 | 8 | .357 (.072)*** | .214, .485 | − .136 (− .440, .194) | ||||
| Treatment setting | 3 | 15 |
| .355 | .004 | .061*** | |||
| Home-based | 2 | 11 | .195 (.175) | − .183, .523 | |||||
| Outpatient clinic | 1 | 4 | .471 (.268) | − .082, .802 | .303 (− .374, .769) | ||||
| Alliance characteristics | |||||||||
| Type of alliance | 3 | 15 |
| .244 | .004 | .043 | |||
| Youth–therapist | 1 | 2 | .488 (.232)* | .018, .781 | |||||
| Parent–therapist | 1 | 5 | .151 (.165) | − .208, .515 | − .364 (− .700, .105) | ||||
| Youth + parent–therapist (averaged or added) | 2 | 8 | .357 (.208) | − .086, .682 | − .158 (.691, .485) | ||||
| Alliance rater | 3 | 15 |
| <.001*** | .004 | .000 | |||
| Youth | 1 | 1 | .707 (.235)** | .347, .886 | |||||
| Parent | 2 | 4 | .034 (.043) | − .060, .126 | − .848 (− .880, − .310)** | ||||
| Therapist | 2 | 10 | .375 (.031) *** | .291, .414 | − .468 (− .775, .016) | ||||
| Outcome characteristics | |||||||||
| Outcome domain | 3 | 15 |
| .493 | .004 | .069 ** | |||
| Youth symptom severity or functioning | 3 | 8 | .302 (.160) | − .039, 580 | |||||
| Parental or family functioning | 1 | 4 | .212 (.174) | − .167, .536 | − .097 (− .324, .142) | ||||
| Goal attainment or therapeutic progress | 1 | 3 | .277 (.175) | − .100, .598 | − .028 (− .265, .213) | ||||
| Outcome rater | 3 | 15 |
| .479 | .004 | .059** | |||
| Youth | 1 | 1 | .275 (.201) | − .161, .621 | |||||
| Parent | 2 | 10 | .192 (.171) | − .182, .517 | − .088 (− .322, .156) | ||||
| Youth and parent combined | 1 | 4 | .471 (.264) | − .077, .800 | .225 (− .469, .747) | ||||
| Outcome timing | 3 | 15 |
| .588 | .006* | .049* | |||
| End of treatment | 1 | 2 | .301 (.136)* | .004, .535 | |||||
| Follow-up | 3 | 13 | .241 (.154) | − .090, .523 | − .055 (− .264, .159) | ||||
ES effect size; CI confidence interval; σ2 level 2 variance between effect sizes (within studies); σ2 level 3 variance between effect sizes (between studies)
The number of studies reflects the number of independent samples
*p < .05, **p < .01, ***p < .001
Fig. 2Trim-and-fill plot level of alliance–outcome association
Fig. 3Trim-and-fill plot split alliance–outcome association
Fig. 4Trim-and-fill plot alliance change score–outcome association